Seelos Therapeutics Net Income 2006-2021 | SEEL

Seelos Therapeutics net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Seelos Therapeutics Annual Net Income
(Millions of US $)
2020 $-19
2019 $-51
2018 $-3
2017 $0
2016 $-7
2015 $-19
2014 $-22
2013 $-17
2012 $-32
2011 $-18
2010 $-30
2009 $-32
2008 $-5
2007 $-9
2006 $-8
2005 $-15
Seelos Therapeutics Quarterly Net Income
(Millions of US $)
2021-06-30 $-9
2021-03-31 $-19
2020-12-31 $-6
2020-09-30 $-4
2020-06-30 $-4
2020-03-31 $-5
2019-12-31 $-11
2019-09-30 $-3
2019-06-30 $-2
2019-03-31 $-36
2018-12-31 $-1
2018-09-30 $-1
2018-06-30 $-0
2018-03-31 $-1
2017-12-31 $-2
2017-09-30 $-4
2017-06-30 $-1
2017-03-31 $8
2016-12-31 $-0
2016-09-30 $-1
2016-06-30 $-3
2016-03-31 $-3
2015-12-31 $-2
2015-09-30 $-5
2015-06-30 $-5
2015-03-31 $-6
2014-12-31 $-17
2014-09-30 $-3
2014-06-30 $2
2014-03-31 $-3
2013-12-31 $-1
2013-09-30 $-3
2013-06-30 $-4
2013-03-31 $-9
2012-12-31 $-20
2012-09-30 $-2
2012-06-30 $-5
2012-03-31 $-5
2011-12-31 $-5
2011-09-30 $-2
2011-06-30 $-8
2011-03-31 $-3
2010-12-31 $-13
2010-09-30 $-3
2010-06-30 $-4
2010-03-31 $-9
2009-12-31 $-31
2009-09-30 $-1
2009-06-30 $-1
2009-03-31 $1
2008-12-31 $1
2008-09-30 $-3
2008-06-30 $2
2008-03-31 $-2
2007-12-31 $-3
2007-09-30 $-2
2007-06-30 $-2
2007-03-31 $-2
2006-12-31 $-2
2006-09-30 $-2
2006-06-30 $-1
2006-03-31 $-3
2005-12-31 $-3
2005-09-30 $-3
2005-06-30 $-5
2005-03-31 $-5
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.240B $0.000B
Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.216B 8.54
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.812B 20.00
Biohaven Pharmaceutical Holding (BHVN) United States $8.815B 0.00
Emergent Biosolutions (EBS) United States $2.763B 6.66
Arcus Biosciences (RCUS) United States $2.321B 0.00
Myovant Sciences (MYOV) United Kingdom $1.993B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.769B 0.00
Zymeworks (ZYME) Canada $1.152B 0.00
Ambrx Biopharma (AMAM) United States $0.431B 0.00
SQZ Biotechnologies (SQZ) United States $0.346B 0.00
Enzo Biochem (ENZ) United States $0.188B 18.43